Open Nav

Urigen Pharmaceuticals, Inc.


  • Date:Thursday, October 18
  • Time:9:00 AM - 9:15 AM
  • Room:Elizabethan B
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Urigen Pharmaceuticals specializes in developing innovative products to ameliorate the cause and symptoms associated with urological ailments, specifically Interstitial Cystitis/Bladder Pain Syndrome ("BPS" or "IC/BPS"). Urology represents a specialty pharmaceutical market of approximately 10,000 physicians in the United States. According to the American Urology Association (the "AUA"), urologists treat a variety of ailments of the urinary tract either surgically or medically. These include treating cancer, infections, stone disease, neurogenic bladder, overactive bladder, incontinence, prostate disease and IC/BPS. Many of these indications, we believe, represent significant, underserved therapeutic markets. We currently have one product candidate, URG101, in clinical development, and two other product candidates, URG501 and URG801, in pre-clinical development.
  • Company
  • Company HQ City:New Jersey
  • Company HQ Country:United States
  • Company HQ State:New Jersey                 
  • CEO/Top Company Official:Dan Vickery
  • Main Therapeutic Focus:Reproductive/Sexual Health
  • Lead Product in Development :URG101
  • Development Phase of Primary Product:Phase II
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :3
  • Size of Last Investment Round:1,500,000
  • Total Amount Raised to Date, In All Rounds:10,000,000